The Quintuple Aim: A New Direction for Healthcare Improvement

By Michael Awood

October 26, 2023

The healthcare industry has faced significant challenges recently which has led to escalating costs. These have also continued to expand the disparities within healthcare worldwide. The COVID-19 pandemic brought these to light, with the marginalised communities experiencing higher rates of infection, morbidity, and mortality. These communities also continued to experience greater care disruptions. But what can be done about this? How could technology look to improve the outcomes and provide value? The quintuple framework proposes valuable aspects to improve healthcare systems and coupled with this, AI technologies can look to scale these improvements.

 

The Quintuple Aim

The need to optimise healthcare outcomes and reduce economic waste is more critical than ever. The triple aim was introduced as a beacon to guide healthcare improvements, focusing on enhancing population health, improving care experience, and promoting cost efficiency. However, the rising burnout rates among physicians and the increasing desire to leave the industry necessitated the inclusion of a fourth aim: addressing provider well-being. Without this, quality improvements would be unsustainable. The fifth aim was updated to include health equity, which ensures that we explicitly address equity and actively explore new efforts to promote it.

The quintuple aims for healthcare improvement are:

  1. Improving population health
  2. Enhancing care experience
  3. Cost Efficiency
  4. Provider Wellbeing
  5. Health Equity

 

The Role of Technology and Policy

Technology, particularly AI, plays a crucial role in achieving these aims. AI can improve access to equitable health, ensure cost-effectiveness through predictive algorithms, and manage procedural or administrative work through virtual assistants. Oracle Health has recently shown its new work in the healthcare space and optimising clinical models through the use of LMMs (multimodal models), by launching their digital assistant. The view is that it reduces the cognitive load on clinicians optimising the clinical delivery process, which ultimately also keeps it human. In turn, improvements to patient safety (increased clinician awareness), experience, and provider well-being are immediately actualised. These in turn allow for the other aims to occur as a direct outcome of these enhancements.

Policies based on these principles are essential for designing effective economic supports. Through explainable AI systems, value-based care incentives, and appropriate demographic data, outcomes can be improved, and care can be enhanced in any resource setting.

 

Cover image taken from: Chess Health Solutions

Reference url

Recent Posts

oral GLP-1 medication
    

Market Leadership in Sight as Eli Lilly’s Oral GLP-1 Medication Orforglipron Succeeds in Phase 3

🌟 Ready for a breakthrough in diabetes management?

Eli Lilly’s oral GLP-1 medication, orforglipron, has completed a successful Phase 3 trial, showing remarkable efficacy in lowering A1C levels and promoting substantial weight loss. As the first oral small molecule GLP-1 receptor agonist, it offers a promising alternative to conventional injectable treatments, potentially improving patient adherence and access.

Dive into the details of this exciting development and what it means for the future of diabetes care!

#SyenzaNews #HealthTech #Innovation #Pharmaceuticals

pediatric thyroid cancer risk
    

Environmental Exposures and Pediatric Thyroid Cancer Risk: Key Findings from a California Study

🌟 Are we overlooking environmental risks in pediatric cancer?

Recent research highlights a troubling link between perinatal exposure to PM2.5 and outdoor artificial light and the increased risk of pediatric thyroid cancer. This pivotal study sheds light on how environmental factors play a critical role in childhood health, particularly among vulnerable populations.

Dive into this important discussion on how addressing these environmental exposures may reduce pediatric thyroid cancer and improve health outcomes for future generations.

#SyenzaNews #EnvironmentalHealth #HealthPolicy #Innovation

capivasertib cost-effectiveness
      

Capivasertib Cost-Effectiveness in Advanced Breast Cancer

💡What’s the strategy to bring capivasertib’s price within reach of breast cancer patients?

A recent study evaluates capivasertib, an AKT inhibitor, as a second-line treatment for advanced breast cancer, revealing that its costs significantly outweigh the added health benefits. The analysis indicates that to be cost-effective, a substantial reduction in its price is necessary.

Delve into the economic implications of this treatment and the pressing need for pricing reforms in healthcare.

#SyenzaNews #HealthEconomics #costeffectiveness #oncology

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.